Sai Life Sciences Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Sai Life Sciences Ltd trades at ₹1,315, in a confirmed uptrend and 57 weeks into that stage. That is +25.8% against its own 200-day average. It sits at 100% of a 52-week range of ₹795 to ₹1,315. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 31 straight weeks.

Today the stock is in a confirmed uptrend — week 57 of stage 2, confirmed. At ₹1,315 it trades +25.8% versus its 200-day average and sits at 100% of its 52-week range (₹795–₹1,315).

Against the market, two honest reads. Cumulative: over the last 1.6 years the stock moved +87% while the NIFTY 500 moved +5% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 31 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Sai Life Sciences Ltd trades at 78.7× P/E, about the priciest it has ever traded. Its long-run median P/E is 64.1×, measured across 0.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 78.7× is about the priciest it has ever traded, against a long-run median of 64.1× measured over 0.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +102.0% against a +66.9% price move — earnings outran the price, pushing the multiple DOWN its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Sai Life Sciences Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

4-Factor Sector Score

63.4/100 — rank 10 of 24 in Pharma - API & CRAMS · 89% evidence confidence

Sai Life Sciences Ltd scores 63.4 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 10. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

The four contributions add to the total exactly: 27.4 + 17.3 + 4.7 + 14 = 63.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Sai Life Sciences Ltd reported ₹602 Cr of revenue in the Mar 26 quarter, +3.8% year on year. That is the 6th straight quarter of year-on-year growth. Over 7 years it has compounded at 17.8% a year. The last full year, FY26, came in at ₹2,192 Cr. The last four reported quarters add to ₹2,191 Cr.

FY26 revenue came in at ₹2,192 Cr (+29.3% on the year), capping 7 years at 17.8% compound. The latest quarter (Mar 26) printed ₹602 Cr, +3.8% year on year — the 6th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +35.7% growth against the decade's 17.8% — the current year is running faster than its own long-run rate.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Sai Life Sciences Ltd's operating margin is 29.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 8 fiscal years the operating margin has ranged 14.0% to 29.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 29.0%, +2.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 14.0%–29.0%, and FY26's 29.0% is the top of that band — a record year.

Why the margin moved: operating margin went +2.1 pp year on year while gross margin went +2.1 pp — the gain came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Sai Life Sciences Ltd earned ₹104 Cr of net profit in the Mar 26 quarter, +18.2% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹349 Cr. The 7-year compound rate is 25.0%. That is 17.3% of the quarter's revenue. The same quarter a year earlier earned ₹88.0 Cr.

Mar 26 profit was ₹104 Cr, +18.2% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹349 Cr (+105.3%), and the 7-year compound rate is 25.0%.

Why profit moved: revenue contributed +3.8% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +67.8% vs revenue +35.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 180% of Sai Life Sciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹509 Cr of operating cash against ₹349 Cr of profit. After ₹640 Cr of capital spending, ₹−131 Cr was left as free cash.

FY26: operating cash of ₹509 Cr against reported profit of ₹349 Cr, leaving free cash of ₹−131 Cr after ₹640 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 180% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 180%: the cash cycle tightened 20 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 3.1× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Sai Life Sciences Ltd's cash conversion cycle runs −24 days in FY26, down from −4 days in FY21. Capital spending ran ₹1,322 Cr over the last 3 years. At FY26 sales of ₹2,192 Cr each day of that cycle holds about ₹6.0 Cr, so roughly ₹−144 Cr sits inside the business at any moment.

FY26: debtors at 62 days, inventory at 97 days — roughly 3.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −24 days, tighter than FY21's −4.

The full loop: cash goes out to suppliers and production on day 0; stock waits 97 days to sell; customers pay about 62 days after that; and suppliers themselves are paid at 182 days — netting out to the −24-day cycle.

In money terms: at FY26 sales of ₹2,192 Cr, each day of the cycle holds about ₹6.0 Cr — so the −24-day loop keeps roughly ₹−144 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹1,322 Cr over the last 3 fiscal years against ₹425 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹270 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Sai Life Sciences Ltd earns a ROCE of 20% in FY26. That is up from a trough of 3% in FY22. Return on invested capital clears the cost of that capital by +1.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 15.9% net margin on 0.60× asset turns.

FY26 ROCE is 20%, recovered from a FY22 trough of 3% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 15.9% net margin × 0.60× asset turns × 1.46× balance-sheet leverage ≈ 13.9% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 13.9% − 12.0% = a +1.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Sai Life Sciences Ltd carries total debt of ₹288 Cr against shareholder equity of ₹2,484 Cr as of Mar 26, a debt-to-equity of 0.12 — effectively unlevered. On the annual view that ratio went from 0.95 in FY24 to 0.12 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹288 Cr against shareholder equity of ₹2,484 Cr — a debt-to-equity of 0.12. On the annual view, debt-to-equity went from 0.95 (FY24) to 0.12 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 20.8 points of Sai Life Sciences Ltd over 6 quarters, the biggest move on the register. That takes domestic institutions to 32.7% of the company. Foreign institutions moved +7.9 points over the same window, to 19.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +20.8 points over 6 quarters to 32.7%; Foreign institutions: +7.9 points over 6 quarters to 19.6%; Promoters: −0.7 points over 6 quarters to 34.5%.

Why the register moved: domestic institutions drove it (+20.8 points), alongside foreign institutions (+7.9 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Sai Life Sciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions